SCROLL DOWN

For press inquiries, please contact:

Marc Destito, Communications Director

Email: mdestito@otsuka.ch
Phone: +41 22 560 60 75

In the News

24 March 2017, Johannesburg, South Africa

Clinical access programme for an MDR-TB medicine launched in South Africa.

31 October 2016, Geneva, Switzerland

The Stop TB Partnership announced Otsuka’s new anti-tuberculosis (TB) compound, to be developed as part of a pan-TB regimen.

8 May 2015, Geneva Switzerland

The WHO published the new edition of its Model List of Essential Medicines, which includes new treatments for multidrug-resistant (MDR-TB).

1 May 2015, Geneva, Switzerland

The WHO released an updated companion handbook to the WHO guidelines for the programmatic management of drug-resistant TB.

Press Releases

25 February, 2016, Munich, Germany

Stop TB Partnership’s Global Drug Facility and Otsuka announce a new private-public partnership to expand worldwide access to an MDR-TB drug.

16 July 2015, Tokyo, Japan

Efficacy results of Otsuka’s drug for extensively drug-resistant TB (XDR-TB) published in the New England Journal of Medicine.

4 July 2014, Tokyo, Japan

The Japanese Ministry of Health, Labour and Welfare approved a medicine developed by Otsuka for treatment of adults with pulmonary MDR-TB.

30 April 2014, Tokyo, Japan

Otsuka Wins European Marketing Authorization for a medicine to treat adult pulmonary MDR-TB.

Information current as of 26-06-2017